MARKET

HBIO

HBIO

Harvard Biosci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.820
+0.070
+1.87%
Opening 11:57 05/27 EDT
OPEN
3.760
PREV CLOSE
3.750
HIGH
3.820
LOW
3.730
VOLUME
81.11K
TURNOVER
175.81K
52 WEEK HIGH
8.75
52 WEEK LOW
3.360
MARKET CAP
157.54M
P/E (TTM)
-24.2232
1D
5D
1M
3M
1Y
5Y
Looking Into Harvard Bioscience's Return On Capital Employed
Harvard Bioscience (NASDAQ:HBIO) brought in sales totaling $28.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 815.92%, resulting in a loss of $6.88 million.
Benzinga · 05/19 14:03
Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks · 05/16 13:35
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday.
Benzinga · 05/04 17:45
Recap: Harvard Bioscience Q1 Earnings
  Harvard Bioscience (NASDAQ:HBIO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:26
Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:25
Harvard Bioscience Non-GAAP EPS of $0.04 misses by $0.02, revenue of $28.78M beats by $0.05M
Harvard Bioscience press release (NASDAQ:HBIO): Q1 Non-GAAP EPS of $0.04 misses by $0.02. Revenue of $28.78M (+6.6% Y/Y) beats by $0.05M.
Seekingalpha · 05/04 11:08
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $28.8M, vs. Street Est of $28.7M
MT Newswires · 05/04 07:10
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q1 EPS $0.04, vs. Street Est of $0.06
MT Newswires · 05/04 07:09
More
No Data
Learn about the latest financial forecast of HBIO. Analyze the recent business situations of Harvard Biosci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HBIO stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 3.820
EPS
Actual
Estimate
0.030.050.070.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 137
Institutional Holdings: 35.70M
% Owned: 86.57%
Shares Outstanding: 41.24M
TypeInstitutionsShares
Increased
34
2.05M
New
14
2.29M
Decreased
34
1.06M
Sold Out
10
641.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+3.33%
Healthcare Equipment & Supplies
+2.19%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Green
Chief Financial Officer
Michael Rossi
Lead Director/Independent Director
Bertrand Loy
Independent Director
Katherine Eade
Independent Director
Alan Edrick
Independent Director
Thomas Loewald
No Data
No Data
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

Webull offers kinds of Harvard Bioscience, Inc. stock information, including NASDAQ:HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.